2 results about "Β2 adrenergic receptor" patented technology

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.

This disclosure relates to novel α2 adrenergic receptor (α2AR) agonists and their uses. In particular, this disclosure relates to imidazole-containing compounds of formula (IA), formula (IB), formula (IC), formula (ID), or formula (II). These compounds may be useful as peripherally selective α2AR agonists for the treatment or prevention of diseases.